Showing 4031-4040 of 5911 results for "".
- Aviceda Announces First Patient Dosed in Part 2 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for GAhttps://modernod.com/news/aviceda-therapeutics-announces-first-patient-dosed-in-part-2-of-the-phase-23-siglec-trial-assessing-avd-104-for-ga/2482092/Aviceda Therapeutics announced it has dosed the first patient in part 2 of the phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “Based on the efficacy and safety we saw in part 1, we moved rapidly to i
- EuroEyes Group Wins SMILE Refractive Laser Eye Surgery Awardhttps://modernod.com/news/euroeyes-group-wins-smile-refractive-laser-eye-surgery-award/2482087/LEC London announced that its parent company EuroEyes Clinic Group, has won the SMILE Laser Operations Award for conducting the highest number of SMILE (Small Incision Lenticule Extraction) laser operations in Europe last year (2023). EuroEyes performed a total of 9,550 SMILE operations
- Ascendis Pharma Forms New Ophthalmology Company Eyconishttps://modernod.com/news/ascendis-pharma-forms-new-ophthalmology-company-eyconis/2482086/Ascendis Pharma A/S announced the formation and launch of Eyconis, a company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally. The new company was developed with Frazier Life Sciences, as well as an investor syndicate that includes RA Capital Man
- Mass Eye and Ear: Retinal Imaging and Genetics Data Used to Predict Future Disease Riskhttps://modernod.com/news/mass-eye-and-ear-retinal-imaging-and-genetics-data-used-to-predict-future-disease-risk/2482082/In a new study published in Science Translational Medicine, physician-researchers from Mass Eye and Ear, and the Broad Institute of MIT and Harvard, combined retinal imaging, genetics and big data to estimate how likely a person is to develop eye and systemic diseases in the future.
- Outlook Therapeutics Receives FDA Agreement Under SPA for 90 Day Noninferiority Study, NORSE EIGHThttps://modernod.com/news/outlook-therapeutics-receives-fda-agreement-under-special-protocol-assessment-for-90-day-noninferiority-study-norse-eight/2482077/Outlook Therapeutics announced that it has received written agreement from the FDA under a special protocol assessment (SPA) for the NORSE EIGHT clinical trial protocol evaluating ONS-5010 in wet age-related macular degeneration (AMD) subjects. Additionally, Outlook Therapeutics announc
- Rayner's RayOne EMV Receives Health Canada Approvalhttps://modernod.com/news/rayners-rayone-emv-receives-health-canada-approval/2482076/Rayner announced the approval of RayOne EMV by Health Canada. Developed in collaboration with Professor Graham Barrett, RayOne EMV is the only patented aspheric IOL that induces controlled positive spherical aberration to slightly extend the depth of focus, according to Rayner [1].
- NIH: New Technique Enhances Quality Control of Lab-Grown Cells for AMD Treatmenthttps://modernod.com/news/nih-new-technique-enhances-quality-control-of-lab-grown-cells-for-amd-treatment/2482074/Researchers at the National Eye Institute (NEI) say they have improved a crucial step in the production of retinal pigment epithelium (RPE) they are testing in a clinical trial as treatment for age-related macular degeneration (AMD). Their technique combines electrochemical cell measurements
- Mega-Analysis Identifies Gene Variants Associated with Glaucoma in People of African Ancestryhttps://modernod.com/news/mega-analysis-identifies-gene-variants-associated-with-glaucoma-in-people-of-african-ancestry/2482072/A new analysis focusing specifically on people of African ancestry identified three gene variants that may be contributing to this population’s susceptibility to developing and being blinded by glaucoma, according to report from the Perelman School of Medicine at the University of Pennsylva
- Sydnexis Appoints Erin Horn as Vice President, Head of Market Accesshttps://modernod.com/news/sydnexis-names-erin-horn-as-vice-president-head-of-market-access/2482071/Sydnexis has announced the appointment of Erin Horn as Vice President, Head of Market Access. Ms. Horn will lead Sydnexis’ market access, pricing, contracting, and go-to-market strategies. With 25 years of industry experience, Ms. Horn has a track record of commercial success
- iuvo BioScience Acquires Promedica International to Expand Ophthalmic Clinical CRO Serviceshttps://modernod.com/news/iuvo-bioscience-acquires-promedica-international-to-expand-ophthalmic-clinical-cro-services/2482070/Partner Research Organization iuvo BioScience announced it has acquired Promedica International (PMI), an ophthalmology-focused clinical CRO. Financial terms of the deal were not disclosed. The companies say the combined organization will support all aspects of opht